Publicación:
On the normative foundations of pharmaceutical regulation

Vista sencilla de ítem
dc.contributor.authorTeira Serrano, David
dc.date.accessioned2024-05-20T18:49:29Z
dc.date.available2024-05-20T18:49:29Z
dc.date.issued2017-06-08
dc.description.abstractI argue that behind the 1962 Food and Drug Administration Act we find a combination of two normative principles: a liberal argument for the protection of pharmaceutical markets (in terms of quality control) and a paternalist argument for the protection of pharmaceutical consumers (in terms of drug safety and efficacy). These normative intuitions go hand in hand with the choice of regulatory testing standards: depending on the values the regulator wants to protect, she will avail herself of different testing methods. I explore two potential justifications for regulatory paternalism, in terms of risk aversion and impartiality. I defend our current regulatory arrangement against socialist and libertarian critiques.en
dc.description.versionversión final
dc.identifier.urihttps://hdl.handle.net/20.500.14468/15626
dc.language.isoen
dc.publisher['Barbara Osimani', 'Adam LaCaze']
dc.relation.centerFacultad de Filosofía
dc.relation.departmentLógica, Historia y Filosofía de la Ciencia
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject.keywordsFDA
dc.subject.keywordsRegulation
dc.subject.keywordsclinical trials
dc.titleOn the normative foundations of pharmaceutical regulationes
dc.typebook parten
dc.typecapítulo de libroes
dspace.entity.typePublication
relation.isAuthorOfPublicationad2bda75-c33c-48e1-aad8-c7eb3cfc04cb
relation.isAuthorOfPublication.latestForDiscoveryad2bda75-c33c-48e1-aad8-c7eb3cfc04cb
Archivos
Colecciones
Capítulos